rheumatic diseases

The company said this week that is has raised $36 million in funding, as it continues efforts to develop its Maverick platform for rapid testing in doctors' offices.

People Transfer

Premium

Fate Therapeutics names Ken Batchelor CSO; SV Life Sciences' Ross and MedImmune Ventures' Amprey join NKT Therapeutics board

NHLBI in late January put out an RFP for the program, which calls for researchers to develop proteomics technologies and apply them to solve clinical puzzles. It is set to begin early next year, shortly after its current two major proteomics initiatives expire.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.